|Promastigotes of Leishmania major, 10×100, Giemsa stain.|
Leishmania major is a species of protozoa found in the genus Leishmania, and is associated with the disease zoonotic cutaneous leishmaniasis (also known as "Aleppo boil," "Baghdad boil," "Bay sore," "Biskra button," "Chiclero ulcer," "Delhi boil," "Kandahar sore," "Lahore sore," "Oriental sore," "Pian bois," and "Uta"). L. major is an intracellular pathogen which infects the macrophages and dendritic cells of the immune system. Though Leishmania species are found on every continent aside from Antarctica, Leishmania major is found only in the Eastern Hemisphere, specifically in Northern Africa, the Middle East, Northwestern China, and Northwestern India.
As a trypanosomatid, L. major begins its lifecycle in amastigote form in the midgut of the main vector, female sand flies (Phlebotomus spp.). Once in the gut of the sand fly, the parasites change from aflagelated amastigotes into
flagellated promastigotes for 1–2 weeks until they are fully developed, a which point they make their way to the proboscis. Upon biting a mammalian host, promastigotes are released into the bloodstream, where they are engulfed by macrophages. Following being engulfed, promastigotes transform into amastigotes. Amastigotes are oval or round, and have a diameter between 2-3μm. Additionally, they contain a large, eccentrically placed nucleus along with a kinetoplast (which holds extracellular DNA). Being equipped to survive the acidic environment inside the phagosomes of macrophages, the amastigotes reproduce through the process of binary fission. At this point the amastigotes are released throughout the body, and can be ingested by female sand flies, thus completing the cycle.
Upon entering the mammalian bloodstream, L. major meets the focal point of infection, the macrophage. As a result of two surface molecules, the protease gp63 and a lipophosphoglycan, promastigotes are able to bind to several macrophage receptors. Promastigote attachment to macrophages is facilitated by a number of receptors, including complement receptors CR1 and CR3, and the receptor for advanced glycosylation end products. Activation of complements occurs far from the cell membrane, and insertion of the membrane attack complex does not occur. This action is what allows the parasite to avoid being lysed, and to persist within the host's macrophages.
The incidence rate of cutaneous leishmaniasis is estimated to be between 1-1.5 million cases a year. However, transmission does not often occur in utero, during blood transfusions, or through interpersonal contact. Thus, the main form of transmission is through the sand fly vector. Sand flies do not fly long distances, and tend to complete their life cycles in areas with a diameter of less than 1 km. Furthermore, because of the propensity of sand flies to seek out shelter in the burrows of small rodents, where L. major is endemic, small mammals such as gerbils and jirds serve as the main reservoirs. Dogs have also been documented as contracting cutaneous leishmaniasis in Egypt and Saudi Arabia, this is rare however, and dogs are not important hosts for L. major.
L. major and its cousin, L. tropica, are recognized as causing the majority of cases of cutaneous leishmaniasis across the Middle East, Northern Africa, and some areas of China and India (as mentioned above). Between 2002 and 2004, over 700 cases of the disease were reported among United States military personnel serving in Iraq.
Upon becoming infected, patients usually present with lesions at the site of the sand fly bite. The infection is acute, and usually has a duration of about 3–6 months. As more and more phagocytic cells engulf promastigotes, prompting the production of amastigotes, nodules form on the skin. These nodules then ulcerate, although due to the variable characteristics of the lesions, species specific identification of the pathogen is impossible. Generally though, lesions appear moist and have raised outer borders, a granulating base, an overlying layer of white purulent exudate, and have been described as "pizza-like." Biopsies of these lesions usually reveal a number of findings including numerous macrophages containing intracellular amastigotes as well as lymphocytes with observed granuloma formation and few parasites.
L. major should be considered in the differential diagnosis of chronic lesions of people who have spent time in areas where it is endemic. However, other pathogens can cause similar lesions and therefore paracoccidiodomycosis, histoplasmosis, sporotrichosis, lobomycosis, lupus vulgaris, Mycobacterium ulcerans, syphilis, cutaneous sarcoidosis, and leprosy should all be considered as well.
Because the host's immune system tends to resolve infection after 3–6 months, treatment of the lesions generally focuses on limiting tissue damage and necrosis. A number of different treatments have yielded results of varying effectiveness in the treatment of L. major caused cutaneous leishmaniasis.
-Intralesional injections of 0.5-2.0mL of 100 mg/ML antimony has also been shown to be effective when injected around the sides of lesions. When 10 such injections were given to patients in Egypt, 85% were cured within 3 months.
The spread of leishmaniasis can be prevented by interrupting the sand fly life cycle or removing or treating pathogen reservoirs. Avoiding sand fly bites is an effective means of avoiding disease for short term visitors to areas where L. major is endemic. This can be accomplished through the use of DEET containing insect repellent, application of insecticides to clothes and bedding, as well as using mosquito nets to cover beds. Sand flies usually bite between dusk and dawn, so preventative measures should be taken during these times.
Though a vaccine does not yet exist that can prevent cutaneous leishmaniasis, it is speculated that one will be developed in the near future. Patients who have recovered from L. major infections develop high- level immunity to the pathogen. In Russia and Israel, soldiers were "immunized" against L. major through the injection of live promastigotes into the buttocks; however, this form of treatment was discontinued in Israel due to the occasional formation of large or slow-healing lesions.
|Wikimedia Commons has media related to Leishmania major.|
- Abdulrahman A. Alrajhi, Elfaki A. Ibrahim, Edward B. De Vol, Mohammad Khairat, Rajab M. Faris & James H. Maguire (March 2002). "Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major". New England Journal of Medicine 346 (12): 891–895. doi:10.1056/NEJMoa011882. PMID 11907288.
- "Leishmania major". Wellcome Trust Sanger Institute, Genome Research Limited. Retrieved 6 December 2012.
- Markell, Edward K.; Voge, Marietta and John, David T. (1992). Medical Parasitology (7th ed.). Philadelphia, PA: W.B. Saunders Company. pp. 148–160. ISBN 0-7216-3411-7.
- Guerrant, Richard L.; Walker, David H., and Weller, Peter F. (2006). Tropical Infectious Diseases: Principles, Pathogens, & Practice (2nd ed.). Philadelphia, PA: Elsevier, Inc. pp. 1095–1113. ISBN 9780443066689.
- "Parasites - Leishmaniasis". Centers for Disease Control and Prevention. Retrieved November 27, 2012.
- Kahn, Cynthia M. and Line, Scott., ed. (2005). The Merck Veterinary Manual (9th ed.). Deluth, GA: Merial Limited. pp. 643–644; 717. ISBN 0-911910-50-6.
- Etges, R; Bouvier J, and Bordier C (1986). "The major surface protein of Leishmania promastigotes is a protease". Journal of Biological Chemistry 261: 9098–9101.
- King, DL; Chang Y-D, and Turco SJ (1987). "Cell surface lipophosphoglycan of Leishmania donovani". Molecular and Biochemical Parasitology 24: 47–53.
- Desjeux, P (1992). "Human leishmaniasis: Epidemiology and public health aspects". World Health Statistics Quarterly 45: 267–275.
- Morsey, TA; Schnur LF, Feinsod FM, Salem AM, Wahba MM, and el Said SM (1987). "Natural infections of Leishmania major in domestic dogs from Alexandria, Egypt". The American Journal of Tropical Medicine and Hygiene 37: 49–52.
- Macpherson CNL, Meslin FX, and Wandeler AI, ed. (2000). Dogs, Zoonoses and Public Health. New York, NY: CABI Publishing. p. 139. ISBN 0-85199-436-9.
- "Ceneters for Disease Control and Prevention: Update: Cutaneous leishmaniasis in U.S military personnel- Southwest/Central Asia". Morbidity and Mortality Weekly Report 53: 264–265. 2004.
- Ridley, DS (1979). "The pathogenesis of cutaneous leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene 73: 150–160.
- Alrajhi, AA; Ibrahim EA, De Vol EB, et al. (2002). "Fluconazole for the treatment of cutaneous leishamaniasis caused by Leishmania major". The New England Journal of Medicine 346: 891–895.
- el-On, J; Halevy S, Grunwald MH, et al. (1992). "Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double blind control study". Journal of the American Academy of Dermatology 27: 227–231.